Professor, Department of Otolaryngology--Head and Neck Surgery
Vanderbilt University Medical Center
Nashville, TN, United States
Christopher T. Wootten, M.D., is an assistant professor of Otolaryngology in the Department of Otolaryngology at Vanderbilt University Medical Center and the Monroe Carell Jr. Children’s Hospital at Vanderbilt. He earned his medical degree at Baylor College of Medicine in Houston. He completed his internship in General Surgery and his residency in Otolaryngology at Vanderbilt University Medical Center. He also completed a two-year fellowship in Pediatric Otolaryngology at Cincinnati Children's Hospital Medical Center. He is the director of the Pediatric Otolaryngology Service supervising the treatment of ear, nose and throat-related disorders in children at Vanderbilt University Medical Center and its satellite locations. His clinical practice encompasses all aspects of Pediatric Otolaryngology, with an emphasis on advanced reconstructive surgery for the adult and pediatric airway, multilevel diagnosis and management of refractory pediatric obstructive sleep apnea, operative management of resonance disorders, and the diagnosis and management of pediatric hearing loss. His research interests include the cellular and molecular basis of acquired laryngotracheal stenosis, the multidisciplinary staging of aerodigestive inflammation, and endoscopic device design and application to natural-orifice surgery in the head and neck. For these endeavors, he holds institutional grants, and he is an investigator on the North American Airway Collaborative (NoAAC), funded by a large Patient-Centered Outcomes Research Institute (PCORI) grant.
Saturday, September 28, 2024
9:30 AM – 9:36 AM EDT
Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.
Airway Anti-Inflammatory Medication Regimen for Pediatric Intensive Care Unit Patients
Sunday, September 29, 2024
10:00 AM – 10:06 AM EDT
Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.